Egg allergy - Pipeline Insight, 2024

Egg allergy - Pipeline Insight, 2024

DelveInsight’s, “Egg Allergy - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Egg Allergy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Egg Allergy Understanding

Egg Allergy: Overview

Egg Allergy develops when immune system of the body becomes sensitized and overreacts to proteins in egg whites and/or yolks. When eggs are eaten, the body recognizes the protein as a foreign substance and sends out chemicals to provide protection against it. Those chemicals cause the symptoms of an allergic reaction. According to the experts, about 2 percent of children are allergic to eggs. Although, studies show that about 70 percent of children with an Egg Allergy will recover from the condition by age of16.

""Egg Allergy - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Egg Allergy pipeline landscape is provided which includes the disease overview and Egg Allergy treatment guidelines. The assessment part of the report embraces, in depth Egg Allergy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Egg Allergy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Egg Allergy R&D. The therapies under development are focused on novel approaches to treat/improve Egg Allergy.

Egg Allergy Emerging Drugs Chapters

This segment of the Egg Allergy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Egg Allergy Emerging Drugs

• AR201 Powder: Aimmune Therapeutics

Aimmune Therapeutics’s AR201 is an investigational biological drug for use in ‘oral immunotherapy’ for Egg Allergy as a treatment to reduce the frequency and severity of allergic reactions following exposure to hen eggs. Currently, undergoing phase 2 of clinical trials.

• Viaskin Egg (Egg Allergy Immunotherapy): DBV Technologies

DBV is exploring Viaskin Egg for the treatment of hen’s Egg Allergy. Hen’s Egg Allergy is one of the most common food allergies in children. Several global studies suggest that Egg Allergy affects 1.5 – 3 percent of young children. DBV began pre-clinical work for Viaskin Egg in 2015, with the goal of initiating a clinical program if these studies are successful. Preclinical development is currently ongoing.

Further product details are provided in the report……..

Egg Allergy: Therapeutic Assessment

This segment of the report provides insights about the different Egg Allergy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Egg Allergy

There are approx. 3+ key companies which are developing the therapies for Egg Allergy. The companies which have their Egg Allergy drug candidates in the mid to advanced stage, i.e. Phase II include, Aimmune Therapeutics and others.

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late-stage products (phase III)
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Egg Allergy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Subcutaneous
• Intravenous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecules
• Natural metabolites
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Egg Allergy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Egg Allergy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Egg Allergy drugs.

Egg Allergy Report Insights

• Egg Allergy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Egg Allergy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Egg Allergy drugs?
• How many Egg Allergy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Egg Allergy?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Egg Allergy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Egg Allergy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Aimmune Therapeutics
• DBV Technologies
• ASIT Biotech

Key Products

• AR201
• Viaskin Egg